BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Malek E, de Lima M, Letterio JJ, Kim BG, Finke JH, Driscoll JJ, Giralt SA. Myeloid-derived suppressor cells: The green light for myeloma immune escape. Blood Rev 2016;30:341-8. [PMID: 27132116 DOI: 10.1016/j.blre.2016.04.002] [Cited by in Crossref: 63] [Cited by in F6Publishing: 61] [Article Influence: 10.5] [Reference Citation Analysis]
Number Citing Articles
1 Zhang L, Zhu Y, Wei X, Chen X, Li Y, Zhu Y, Xia J, Huang Y, Huang Y, Wang J, Pang Z. Nanoplateletsomes restrain metastatic tumor formation through decoy and active targeting in a preclinical mouse model. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.01.005] [Reference Citation Analysis]
2 Lv M, Wang K, Huang XJ. Myeloid-derived suppressor cells in hematological malignancies: friends or foes. J Hematol Oncol 2019;12:105. [PMID: 31640764 DOI: 10.1186/s13045-019-0797-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
3 Chen L, Qiu X, Wang X, He J. FAP positive fibroblasts induce immune checkpoint blockade resistance in colorectal cancer via promoting immunosuppression. Biochem Biophys Res Commun 2017;487:8-14. [PMID: 28302482 DOI: 10.1016/j.bbrc.2017.03.039] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 7.2] [Reference Citation Analysis]
4 Wang Z, Jiang R, Li Q, Wang H, Tao Q, Zhai Z. Elevated M-MDSCs in Circulation Are Indicative of Poor Prognosis in Diffuse Large B-Cell Lymphoma Patients. J Clin Med 2021;10:1768. [PMID: 33921711 DOI: 10.3390/jcm10081768] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Bae MH, Park CJ, Suh C. Increased Monocytic Myeloid-Derived Suppressor Cells in Whole Blood Predict Poor Prognosis in Patients with Plasma Cell Myeloma. J Clin Med 2021;10:4717. [PMID: 34682840 DOI: 10.3390/jcm10204717] [Reference Citation Analysis]
6 Khalife J, Sanchez JF, Pichiorri F. The Emerging Role of Extracellular Vesicle-Associated RNAs in the Multiple Myeloma Microenvironment. Front Oncol 2021;11:689538. [PMID: 34235082 DOI: 10.3389/fonc.2021.689538] [Reference Citation Analysis]
7 Navashenaq JG, Zamani P, Nikpoor AR, Tavakkol-Afshari J, Jaafari MR. Doxil chemotherapy plus liposomal P5 immunotherapy decreased myeloid-derived suppressor cells in murine model of breast cancer. Nanomedicine 2020;24:102150. [PMID: 31931230 DOI: 10.1016/j.nano.2020.102150] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
8 Shah N, Aiello J, Avigan DE, Berdeja JG, Borrello IM, Chari A, Cohen AD, Ganapathi K, Gray L, Green D, Krishnan A, Lin Y, Manasanch E, Munshi NC, Nooka AK, Rapoport AP, Smith EL, Vij R, Dhodapkar M. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. J Immunother Cancer 2020;8:e000734. [PMID: 32661116 DOI: 10.1136/jitc-2020-000734] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
9 Wang Y, Jia A, Bi Y, Wang Y, Liu G. Metabolic Regulation of Myeloid-Derived Suppressor Cell Function in Cancer. Cells 2020;9:E1011. [PMID: 32325683 DOI: 10.3390/cells9041011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
10 Kang MA, Lee J, Ha SH, Lee CM, Kim KM, Jang KY, Park SH. Interleukin4Rα (IL4Rα) and IL13Rα1 Are Associated with the Progress of Renal Cell Carcinoma through Janus Kinase 2 (JAK2)/Forkhead Box O3 (FOXO3) Pathways. Cancers (Basel) 2019;11:E1394. [PMID: 31540495 DOI: 10.3390/cancers11091394] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
11 Tadmor T, Levy I, Vadasz Z. Hierarchical Involvement of Myeloid-Derived Suppressor Cells and Monocytes Expressing Latency-Associated Peptide in Plasma Cell Dyscrasias. Turk J Haematol 2018;35:116-21. [PMID: 29589834 DOI: 10.4274/tjh.2018.0022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Li Y, Zhang T, Liu Q, He J. PEG-Derivatized Dual-Functional Nanomicelles for Improved Cancer Therapy. Front Pharmacol 2019;10:808. [PMID: 31379579 DOI: 10.3389/fphar.2019.00808] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
13 Ismail MM, Abdulateef NAB. Absolute Monocyte Count is Superior than Absolute Lymphocyte Count at Day 28 as an Independent Prognostic Factor in Acute Myeloid Leukemia. Indian J Hematol Blood Transfus 2019;35:100-8. [PMID: 30828155 DOI: 10.1007/s12288-018-0976-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Bonavida B, Chouaib S. Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance. Ann Oncol 2017;28:457-67. [PMID: 27864216 DOI: 10.1093/annonc/mdw615] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
15 Merino AM, Mehta RS, Luo X, Kim H, De For T, Janakiram M, Cooley S, Wangen R, Cichocki F, Weisdorf DJ, Miller JS, Bachanova V. Early Adaptive Natural Killer Cell Expansion Is Associated with Decreased Relapse After Autologous Transplantation for Multiple Myeloma. Transplant Cell Ther 2021;27:310.e1-6. [PMID: 33836870 DOI: 10.1016/j.jtct.2020.10.023] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Zanwar S, Nandakumar B, Kumar S. Immune-based therapies in the management of multiple myeloma. Blood Cancer J 2020;10:84. [PMID: 32829378 DOI: 10.1038/s41408-020-00350-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
17 Sweiss K, Lee J, Mahmud N, Calip GS, Park Y, Mahmud D, Rondelli D, Patel PR. Combined immune score of lymphocyte to monocyte ratio and immunoglobulin levels predicts treatment-free survival of multiple myeloma patients after autologous stem cell transplant. Bone Marrow Transplant 2020;55:199-206. [PMID: 31527821 DOI: 10.1038/s41409-019-0681-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
18 Serrano-Del Valle A, Anel A, Naval J, Marzo I. Immunogenic Cell Death and Immunotherapy of Multiple Myeloma. Front Cell Dev Biol 2019;7:50. [PMID: 31041312 DOI: 10.3389/fcell.2019.00050] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 18.0] [Reference Citation Analysis]
19 Díaz-Tejedor A, Lorenzo-Mohamed M, Puig N, García-Sanz R, Mateos MV, Garayoa M, Paíno T. Immune System Alterations in Multiple Myeloma: Molecular Mechanisms and Therapeutic Strategies to Reverse Immunosuppression. Cancers (Basel) 2021;13:1353. [PMID: 33802806 DOI: 10.3390/cancers13061353] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
20 Lewinsky H, Gunes EG, David K, Radomir L, Kramer MP, Pellegrino B, Perpinial M, Chen J, He TF, Mansour AG, Teng KY, Bhattacharya S, Caserta E, Troadec E, Lee P, Feng M, Keats J, Krishnan A, Rosenzweig M, Yu J, Caligiuri MA, Cohen Y, Shevetz O, Becker-Herman S, Pichiorri F, Rosen S, Shachar I. CD84 is a regulator of the immunosuppressive microenvironment in multiple myeloma. JCI Insight 2021;6:141683. [PMID: 33465053 DOI: 10.1172/jci.insight.141683] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Bednarska K, Nath K, Nicol W, Gandhi MK. Immunity reloaded: Deconstruction of the PD-1 axis in B cell lymphomas. Blood Rev 2021;:100832. [PMID: 33896649 DOI: 10.1016/j.blre.2021.100832] [Reference Citation Analysis]
22 Burwick N. Vitamin D and plasma cell dyscrasias: reviewing the significance. Ann Hematol 2017;96:1271-7. [PMID: 28502031 DOI: 10.1007/s00277-017-3016-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
23 Terme M, Tanchot C. [Immune system and tumors]. Ann Pathol 2017;37:11-7. [PMID: 28159405 DOI: 10.1016/j.annpat.2016.12.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
24 Ho M, Goh CY, Patel A, Staunton S, O'Connor R, Godeau M, Bianchi G. Role of the Bone Marrow Milieu in Multiple Myeloma Progression and Therapeutic Resistance. Clin Lymphoma Myeloma Leuk 2020;20:e752-68. [PMID: 32651110 DOI: 10.1016/j.clml.2020.05.026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
25 Zhou H, Yang P, Li H, Zhang L, Li J, Zhang T, Sheng C, Wang J. Carbon ion radiotherapy boosts anti-tumour immune responses by inhibiting myeloid-derived suppressor cells in melanoma-bearing mice. Cell Death Discov 2021;7:332. [PMID: 34732697 DOI: 10.1038/s41420-021-00731-6] [Reference Citation Analysis]
26 Rafei H, Haroun F, Tabbara IA. Novel Immunotherapeutic Agents for the Treatment of Multiple Myeloma. Am J Clin Oncol 2019;42:317-29. [PMID: 30557165 DOI: 10.1097/COC.0000000000000506] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
27 Solimando AG, Vacca A, Ribatti D. A Comprehensive Biological and Clinical Perspective Can Drive a Patient-Tailored Approach to Multiple Myeloma: Bridging the Gaps between the Plasma Cell and the Neoplastic Niche. J Oncol 2020;2020:6820241. [PMID: 32508920 DOI: 10.1155/2020/6820241] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
28 Dosani T, Covut F, Beck R, Driscoll JJ, de Lima M, Malek E. Significance of the absolute lymphocyte/monocyte ratio as a prognostic immune biomarker in newly diagnosed multiple myeloma. Blood Cancer J 2017;7:e579. [PMID: 28665418 DOI: 10.1038/bcj.2017.60] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
29 Walter RB. Expanding use of CD33-directed immunotherapy. Expert Opin Biol Ther 2020;20:955-8. [PMID: 32580591 DOI: 10.1080/14712598.2020.1788540] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
30 Kostopoulos IV, Ntanasis-Stathopoulos I, Gavriatopoulou M, Tsitsilonis OE, Terpos E. Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches. Front Oncol 2020;10:860. [PMID: 32537439 DOI: 10.3389/fonc.2020.00860] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
31 Pang X, Fan HY, Tang YL, Wang SS, Cao MX, Wang HF, Dai LL, Wang K, Yu XH, Wu JB, Tang YJ, Liang XH. Myeloid derived suppressor cells contribute to the malignant progression of oral squamous cell carcinoma. PLoS One 2020;15:e0229089. [PMID: 32092078 DOI: 10.1371/journal.pone.0229089] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
32 Zahid MF, Lazarus HM, Ringdén O, Barrett JA, Gale RP, Hashmi SK. Can we prevent or treat graft-versus-host disease with cellular-therapy? Blood Rev 2020;43:100669. [PMID: 32089398 DOI: 10.1016/j.blre.2020.100669] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
33 Plzák J, Bouček J, Bandúrová V, Kolář M, Hradilová M, Szabo P, Lacina L, Chovanec M, Smetana K Jr. The Head and Neck Squamous Cell Carcinoma Microenvironment as a Potential Target for Cancer Therapy. Cancers (Basel) 2019;11:E440. [PMID: 30925774 DOI: 10.3390/cancers11040440] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 6.7] [Reference Citation Analysis]
34 Rodríguez-Otero P, Paiva B, Engelhardt M, Prósper F, San Miguel JF. Is immunotherapy here to stay in multiple myeloma? Haematologica 2017;102:423-32. [PMID: 28082344 DOI: 10.3324/haematol.2016.152504] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
35 Marchica V, Costa F, Donofrio G, Giuliani N. Oncolytic Virotherapy and Microenvironment in Multiple Myeloma. Int J Mol Sci 2021;22:2259. [PMID: 33668361 DOI: 10.3390/ijms22052259] [Reference Citation Analysis]
36 Morelli E, Gullà A, Rocca R, Federico C, Raimondi L, Malvestiti S, Agosti V, Rossi M, Costa G, Giavaresi G, Azab KA, Cagnetta A, Cea M, Tagliaferri P, Neri A, Munshi NC, Viglietto G, Tassone P, Amodio N. The Non-Coding RNA Landscape of Plasma Cell Dyscrasias. Cancers (Basel) 2020;12:E320. [PMID: 32019064 DOI: 10.3390/cancers12020320] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
37 Ai L, Mu S, Sun C, Fan F, Yan H, Qin Y, Cui G, Wang Y, Guo T, Mei H, Wang H, Hu Y. Myeloid-derived suppressor cells endow stem-like qualities to multiple myeloma cells by inducing piRNA-823 expression and DNMT3B activation. Mol Cancer 2019;18:88. [PMID: 30979371 DOI: 10.1186/s12943-019-1011-5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 11.0] [Reference Citation Analysis]
38 Nijhof IS, van de Donk NWCJ, Zweegman S, Lokhorst HM. Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update. Drugs 2018;78:19-37. [PMID: 29188449 DOI: 10.1007/s40265-017-0841-y] [Cited by in Crossref: 59] [Cited by in F6Publishing: 55] [Article Influence: 14.8] [Reference Citation Analysis]
39 Offidani M, Corvatta L. A review discussing elotuzumab and its use in the second-line plus treatment of multiple myeloma. Future Oncol 2018;14:319-29. [PMID: 29091475 DOI: 10.2217/fon-2017-0371] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
40 Lee MJ, Park SY, Ko JH, Lee HJ, Ryu JS, Park JW, Khwarg SI, Yoon SO, Oh JY. Mesenchymal stromal cells promote B-cell lymphoma in lacrimal glands by inducing immunosuppressive microenvironment. Oncotarget 2017;8:66281-92. [PMID: 29029511 DOI: 10.18632/oncotarget.19971] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
41 Cheng Z, Zhang D, Gong B, Wang P, Liu F. CD163 as a novel target gene of STAT3 is a potential therapeutic target for gastric cancer. Oncotarget 2017;8:87244-62. [PMID: 29152078 DOI: 10.18632/oncotarget.20244] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
42 Byrgazov K, Lind T, Rasmusson AJ, Andersson C, Slipicevic A, Lehmann F, Gullbo J, Melhus H, Larsson R, Fryknäs M. Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes. Bone Rep 2021;15:101098. [PMID: 34150958 DOI: 10.1016/j.bonr.2021.101098] [Reference Citation Analysis]
43 Hou A, Hou K, Huang Q, Lei Y, Chen W. Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors. Front Immunol 2020;11:783. [PMID: 32508809 DOI: 10.3389/fimmu.2020.00783] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
44 Bizymi N, Bjelica S, Kittang AO, Mojsilovic S, Velegraki M, Pontikoglou C, Roussel M, Ersvær E, Santibañez JF, Lipoldová M, Papadaki HA. Myeloid-Derived Suppressor Cells in Hematologic Diseases: Promising Biomarkers and Treatment Targets. Hemasphere 2019;3:e168. [PMID: 31723807 DOI: 10.1097/HS9.0000000000000168] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 6.7] [Reference Citation Analysis]
45 Ye R, Kundrapu S, Gerson SL, Driscoll JJ, Beck R, Ali N, Landgren O, VanHeeckeren W, Luo G, Kroger N, Caimi P, De Lima M, Malek E. Immune Signatures Associated With Clonal Isotype Switch After Autologous Stem Cell Transplantation for Multiple Myeloma. Clin Lymphoma Myeloma Leuk 2019;19:e213-20. [PMID: 30878316 DOI: 10.1016/j.clml.2018.12.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
46 Romano A, Parrinello NL, La Cava P, Tibullo D, Giallongo C, Camiolo G, Puglisi F, Parisi M, Pirosa MC, Martino E, Conticello C, Palumbo GA, Di Raimondo F. PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy. Expert Rev Mol Diagn 2018;18:675-83. [PMID: 29707981 DOI: 10.1080/14737159.2018.1470929] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 8.0] [Reference Citation Analysis]
47 McCachren SS, Dhodapkar KM, Dhodapkar MV. Co-evolution of Immune Response in Multiple Myeloma: Implications for Immune Prevention. Front Immunol 2021;12:632564. [PMID: 33717170 DOI: 10.3389/fimmu.2021.632564] [Reference Citation Analysis]
48 Jiao Y, Yi M, Xu L, Chu Q, Yan Y, Luo S, Wu K. CD38: targeted therapy in multiple myeloma and therapeutic potential for solid cancers. Expert Opin Investig Drugs 2020;29:1295-308. [PMID: 32822558 DOI: 10.1080/13543784.2020.1814253] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
49 Hou A, Hou K, Huang Q, Lei Y, Chen W. Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors. Front Immunol 2020;11:783. [PMID: 32508809 DOI: 10.3389/fimmu.2020.00783] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
50 Chen S, Rivaud P, Park JH, Tsou T, Charles E, Haliburton JR, Pichiorri F, Thomson M. Dissecting heterogeneous cell populations across drug and disease conditions with PopAlign. Proc Natl Acad Sci U S A 2020;117:28784-94. [PMID: 33127759 DOI: 10.1073/pnas.2005990117] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
51 Nahas MR, Rosenblatt J, Lazarus HM, Avigan D. Anti-cancer vaccine therapy for hematologic malignancies: An evolving era. Blood Rev 2018;32:312-25. [PMID: 29475779 DOI: 10.1016/j.blre.2018.02.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
52 Al-Hujaily EM, Oldham RA, Hari P, Medin JA. Development of Novel Immunotherapies for Multiple Myeloma. Int J Mol Sci 2016;17:E1506. [PMID: 27618026 DOI: 10.3390/ijms17091506] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
53 Dong PY, Huang LF, Sun HY. [Research progress of bone marrow microenvironment abnormalities in myelodysplastic syndrome]. Zhonghua Xue Ye Xue Za Zhi 2017;38:643-6. [PMID: 28810341 DOI: 10.3760/cma.j.issn.0253-2727.2017.07.022] [Reference Citation Analysis]
54 Perez C, Botta C, Zabaleta A, Puig N, Cedena MT, Goicoechea I, Alameda D, San José-Eneriz E, Merino J, Rodríguez-Otero P, Maia C, Alignani D, Maiso P, Manrique I, Lara-Astiaso D, Vilas-Zornoza A, Sarvide S, Riillo C, Rossi M, Rosiñol L, Oriol A, Blanchard MJ, Rios R, Sureda A, Martin J, Martinez R, Bargay J, de la Rubia J, Hernandez MT, Martinez-Lopez J, Orfao A, Agirre X, Prosper F, Mateos MV, Lahuerta JJ, Blade J, San-Miguel JF, Paiva B. Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma. Blood 2020;136:199-209. [PMID: 32325491 DOI: 10.1182/blood.2019004537] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 22.0] [Reference Citation Analysis]
55 Palumbo GA, Parrinello NL, Giallongo C, D'Amico E, Zanghì A, Puglisi F, Conticello C, Chiarenza A, Tibullo D, Raimondo FD, Romano A. Monocytic Myeloid Derived Suppressor Cells in Hematological Malignancies. Int J Mol Sci 2019;20:E5459. [PMID: 31683978 DOI: 10.3390/ijms20215459] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
56 Ha Y, Mohamed Ali MA, Petersen MM, Harmsen WS, Therneau TM, Lee HC, Ryoo BY, Bampoh S, Valles KA, Mady M, Missula VR, Prasai K, Roberts LR, Kim KM. Lymphocyte to monocyte ratio-based nomogram for predicting outcomes of hepatocellular carcinoma treated with sorafenib. Hepatol Int 2020;14:776-87. [PMID: 32740886 DOI: 10.1007/s12072-020-10076-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
57 Dutoit V, Migliorini D, Dietrich PY, Walker PR. Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites? Front Oncol 2016;6:256. [PMID: 28003994 DOI: 10.3389/fonc.2016.00256] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
58 Lin Y, Yuan Q, Qian F, Qin C, Cao Q, Wang M, Chu H, Zhang Z. Polymorphism rs4787951 in IL-4R contributes to the increased risk of renal cell carcinoma in a Chinese population. Gene 2019;685:242-7. [PMID: 30472377 DOI: 10.1016/j.gene.2018.11.070] [Reference Citation Analysis]
59 Zhou Y, Zhu Y, Xie Y, Ma X. The Role of Long Non-coding RNAs in Immunotherapy Resistance. Front Oncol 2019;9:1292. [PMID: 31850199 DOI: 10.3389/fonc.2019.01292] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
60 Yuan SJ, Xu YH, Wang C, An HC, Xu HZ, Li K, Komatsu N, Zhao L, Chen X. Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer. J Nanobiotechnology 2019;17:110. [PMID: 31623629 DOI: 10.1186/s12951-019-0541-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
61 Yan H, Zheng G, Qu J, Liu Y, Huang X, Zhang E, Cai Z. Identification of key candidate genes and pathways in multiple myeloma by integrated bioinformatics analysis. J Cell Physiol 2019;234:23785-97. [PMID: 31215027 DOI: 10.1002/jcp.28947] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
62 Lee SE, Lim JY, Kim TW, Ryu DB, Park SS, Jeon YW, Yoon JH, Cho BS, Eom KS, Kim YJ, Kim HJ, Lee S, Cho SG, Kim DW, Lee JW, Min CK. Different role of circulating myeloid-derived suppressor cells in patients with multiple myeloma undergoing autologous stem cell transplantation. J Immunother Cancer 2019;7:35. [PMID: 30732646 DOI: 10.1186/s40425-018-0491-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
63 Kuwahara-Ota S, Shimura Y, Steinebach C, Isa R, Yamaguchi J, Nishiyama D, Fujibayashi Y, Takimoto-Shimomura T, Mizuno Y, Matsumura-Kimoto Y, Tsukamoto T, Chinen Y, Kobayashi T, Horiike S, Taniwaki M, Gütschow M, Kuroda J. Lenalidomide and pomalidomide potently interfere with induction of myeloid-derived suppressor cells in multiple myeloma. Br J Haematol 2020;191:784-95. [PMID: 32558939 DOI: 10.1111/bjh.16881] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
64 Bauer D, Redmon N, Mazzio E, Soliman KF. Apigenin inhibits TNFα/IL-1α-induced CCL2 release through IKBK-epsilon signaling in MDA-MB-231 human breast cancer cells. PLoS One 2017;12:e0175558. [PMID: 28441391 DOI: 10.1371/journal.pone.0175558] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 6.8] [Reference Citation Analysis]
65 Zhou L, Qi S, Yan C, Jin HM, Xu J, Ma L, Guan J, Xia S. [Myeloid-derived suppressor cells in peripheral blood of multiple myeloma]. Zhonghua Xue Ye Xue Za Zhi 2017;38:545-7. [PMID: 28655102 DOI: 10.3760/cma.j.issn.0253-2727.2017.06.016] [Reference Citation Analysis]
66 Tumino N, Di Pace AL, Besi F, Quatrini L, Vacca P, Moretta L. Interaction Between MDSC and NK Cells in Solid and Hematological Malignancies: Impact on HSCT. Front Immunol 2021;12:638841. [PMID: 33679798 DOI: 10.3389/fimmu.2021.638841] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]